Phase III study of HP-3150

Phase III study of HP-3150 in patients with cancer pain

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223595

Enrollment

480

Registered

2017-07-20

Start date

2017-07-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

investigational material(s) Generic name etc : diclofenac sodium INN of investigational material : diclofenac Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients confirmed to have various types of cancer who were informed about their disease.

Exclusion criteria

Exclusion criteria: - Patients with abnormalities at the planned application site. - Patients with a serious hematologic disorder, hepatic dysfunction, renal dysfunction, hypertension, or heart failure. - Patients who have undergone an operation or nerve block, etc. that may affect assessment of pain.

Design outcomes

Primary

Measure	Time frame
efficacy Efficacy	—

Secondary

Measure	Time frame
safety Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026